aTyr Pharma, Inc.

Yahoo · Apr 8, 2026

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

The growing interstitial lung disease market is supported by the widespread use of foundational and supportive treatments such as corticosteroids, immunosuppressants, biologics, and adjunct therapies like cough suppressants. At the same time, the introduction of advanced pipeline candidates, including seralutinib (Gossamer Bio/Chiesi Farmaceutici), L606 (Liquidia Corporation), N-115 (Emphycorp), efzofitimod (aTyr Pharma), and others, is expanding the treatment landscape by addressing multiple di

Benzinga · Mar 5, 2026

aTyr Pharma Q4 EPS $(0.14) Beats $(0.16) Estimate

aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 13.04 percent. This is a 22.22 percent increase over losses of $(0.18) per share from the

Benzinga · Feb 3, 2026

aTyr Pharma Announces Mid-April 2026 FDA Meeting To Discuss Path Forward For Efzofitimod In Pulmonary Sarcoidosis After Phase 3 Study

globenewswire.com · Dec 11, 2025

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches tied to disclosures around the Phase 3 EFZO-FIT clinical trial.